Recently, the gene therapy field has begun to experience clinical successes in a number of different diseases using various approaches and vectors. The workshop Gene Therapy: Charting a Future Course, sponsored by the National Institutes of Health (NIH) Office of Biotechnology Activities, brought together early and mid-career researchers to discuss the key scientific challenges and opportunities, ethical and communication issues, and NIH and foundation resources available to facilitate further clinical advances.
Get full access to this article
View all access options for this article.
References
1.
AiutiA., CattaneoF., GalimbertiS., et al. (2009). Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med., 360, 448–458.
2.
AsokanA., and SamulskiR.J. (2013). An emerging adeno-associated viral vector pipeline for cardiac gene therapy. Hum. Gene Ther., 24, 906–913.
3.
AsokanA., SchafferD., and SamulskiR.J. (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther., 20, 699–708.
4.
BoothC., GasparH.B., and ThrasherA. (2011). Gene therapy for primary immunodeficiency. Curr. Opin. Pediatr., 23, 659–666.
5.
BoyeS.E., BoyeS.L., PangJ., et al. (2010). Functional and behavioral restoration of vision by gene therapy in the guanylate cyclase-1 (GC1) knockout mouse. PLoS One, 5, e11306.
6.
BoyeS.L., ConlonT., ErgerK., et al. (2011). Long-term preservation of cone photoreceptors and restoration of cone function by gene therapy in the guanylate cyclase-1 knockout (GC1KO) mouse. Invest. Ophthalmol. Vis. Sci., 52, 7098–7108.
7.
BoyeS.E., AlexanderJ.J., BoyeS.L., et al. (2012). The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina. Hum. Gene Ther., 23, 1101–1115.
8.
BoyeS.L., PeshenkoI.V., HuangW.C., et al. (2013). AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis. Hum. Gene Ther., 24, 189–202.
9.
CandottiF., ShawK.L., MuulL., et al. (2012). Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood, 120, 3635–3646.
10.
DavilaM., RiviereI., WangX., et al. (2014). Efficacy and toxicity management of 19–28z CAR T cell therapy in a B cell acute lymphoblastic leukemia. Sci. Transl. Med., 6, 224ra25.
11.
DavisP. (2012). An unparalleled engine for discovery and clinical introduction: the clinical and translational science awards and gene therapy. Hum. Gene Ther., 23, 251–253.
12.
DeakinC.T., AlexanderI.E., and KerridgeI. (2009). Accepting risk in clinical research: is the gene therapy field becoming too risk-averse?. Mol. Ther., 17, 1842–1848.
13.
De OliveiraS.N., RyanC., GiannoniF., et al. (2013). Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy. Hum. Gene Ther., 24, 824–839.
14.
DiStasiA., TeyS.-K., DottiG., et al. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med., 365, 1673–1683.
15.
DykaF., BoyeS.L., ChiodoV., et al., (2014). Dual adeno-associated virus vectors result in efficient in vitro and in vivo expression of an oversized gene, MYO7A. Hum. Gene Ther. Methods, 25, 166–177.
16.
EshharZ., WaksT., GrossG., et al. (1993). Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA, 90, 720–724.
17.
FischerA., Hacein-Bey-AbinaS., and Cavazana-CalvoM. (2013). Gene therapy of primary T cell immunodeficiencies. Gene, 525, 170–173.
GerdemannU., KatariU., PapadopoulouA., et al. (2013). Safety and clinical efficacy of rapidly-generated trivirus–directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol. Ther., 21, 2113–2121.
20.
GiannoniF., HardeeC.L., WherleyJ., et al. (2013). Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells. Mol. Ther., 21, 1044–1054.
21.
GradazZ., HegdeM., ByrdT., et al. (2013). TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy, Mal. Ther. Nuc. Acids., 2, e105.
22.
GruppS., KalosM., BarrettD., et al. (2013.) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med., 368, 1509–1518.
23.
Hacein-Bey-AbinaS., HauerJ., LimA., et al. (2010). Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med., 363, 355–364.
24.
HauswirthW., AlemanT., KaushalS., et al. (2008). Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum. Gene Ther., 19, 979–990.
25.
HegdeM., CorderA., ChowK., et al. (2013). Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol. Ther., 21, 2087–2101.
26.
JacobsonS.G., CideciyanA.V., PeshenkoI.V., et al. (2013). Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants. Hum. Mol. Genet., 22, 168–183.
27.
KaminskyS., RosengartT., RosenbergJ., et al. (2013). Gene therapy to stimulate angiogenesis to treat diffuse coronary artery disease. Hum. Gene Ther., 24, 948–963.
28.
KimmelmanJ. (2009). Tomorrow, interrupted? Risk, ethics, and medical advance in gene transfer. Mol. Ther., 17, 1838–1839.
29.
KudvaY., OhmineS., GrederL., et al. (2012). Transgene-free disease-specific induced pluripotent stem cells from patients with type 1 and type 2 diabetes. Stem Cells Trans. Med., 1, 451–461.
30.
LiuJ., WallaceM., Garwick-CoppensS., et al. (2014). RNAi-mediated gene silencing of mutant myotilin improves myopathy in LGMD1A mice. Mol. Ther. Nucleic Acids, 3, e160.
31.
LopesV.S., BoyeS.E., LouieC.M., et al. (2013). Retinal gene therapy with a large MYO7A cDNA using adeno-associated virus. Gene Ther., 20, 824–833.
32.
MaguireA., SimonelliF., PierceE., et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med., 358, 2240–2248.
33.
MukherjeeS., and ThrasherA. (2013). Gene therapy for PIDs: progress, pitfalls, and prospects. Gene, 525, 174–181.
34.
NathwaniA.C., TuddenhamE., RangarajanS., et al. (2011) Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.N. Engl. J. Med., 365, 2357–2365.
35.
PorterD., LevineB., KalosM., et al. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med., 365, 725–733.
36.
PuleM., FinneyH., andLawsonA., et al. (2003). Artificial T cell receptors. Cytotherapy, 5, 211–226.
37.
PuleM., SavoldoB., MyersG.D., et al. (2008). Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med., 14, 1264–1270.
38.
RomeroZ., UrbinatiF., GeigerS., et al. (2013). β-globin gene transfer to human bone marrow for sickle cell disease. J. Clin. Invest., 123, 3317–3330.
39.
SavoldoB., RamosC., LiuE., et al. (2011). CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest., 121, 1822–1826.
40.
SondhiD., JohnsonL., PurpuraK., et al. (2012). Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis. Hum. Gene Ther. Methods, 23, 324–335.
41.
StroesE., NiemanM., MeulenbergJ., et al. (2008). Intramuscular administration of AAV1-lipoprotein lipaseS447× lowers triglycerides in lipoprotein lipase-deficient patients. Arterioschler. Thromb. Vasc. Biol., 28, 2303–2304.
42.
ThatavaT., KudvaY., EdukullaR., et al. (2013). Intrapatient variations in type 1 diabetes-specific iPS cell differentiation into insulin-producing cells. Mol. Ther., 21, 228–239.
43.
TillB., JensenM., WangJ., et al. (2013). CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4–1 BB domains: pilot clinical trial results. Blood, 119, 3940–3950.
44.
VandenDriesscheT., and ChuahM.K. (2012). Clinical progress in gene therapy: sustained partial correction of the bleeding disorder in patients suffering from severe hemophilia B. Hum. Gene Ther., 23, 4–6.
45.
VannemanM., and DranoffG. (2012). Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer, 12, 237–251.
46.
WadeN. (2011). Treatment of blood disease is gene therapy landmark. New York Times, December. 11.
47.
ZallinD. (2000). US gene therapy in crisis. Trends Genet., 6, 272–275.
